CAR-T cell therapy for blood cancers based on tumor traits
Part of Blood & lymphatic clinical trials.
This study looks at how well CAR-T cell therapy—a treatment that uses your own immune cells to fight cancer—works for people with certain blood cancers like lymphoma, acute lymphoblastic leukemia, or multiple myeloma. The goal is to see if the characteristics of the tumor affect how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer such as lymphoma, acute lymphoblastic leukemia (ALL), or multiple myeloma (MM).
- You are 15 years old or older.
- You are already enrolled in a CAR-T cell treatment program.
- You weigh at least 58 kilograms (about 128 pounds).
- You have given written consent to join the study (or a parent or guardian if under 18).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new type of immunotherapy that uses your own immune cells, modified in a lab, to find and attack cancer cells in blood cancers like leukemia, lymphoma, and multiple myeloma. It is for people whose cancer has come back or not responded to standard treatments.
This trial studies whether a CAR-T cell therapy is safe and effective for people with relapsed or refractory lymphoma, leukemia, or myeloma whose tumors have the right target markers. You may qualify if your health (heart, lungs, kidneys, liver) and blood counts are within required limits.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to fight blood cancers that have come back or stopped responding to standard treatments. The therapy uses your own immune cells, which are modified in a lab to better recognize and attack cancer cells.
This trial tests a new CAR-T cell therapy for people with certain blood cancers (B-cell acute lymphoblastic leukemia, B-cell lymphoma, or multiple myeloma) that have come back or stopped responding to treatment. The therapy uses your own immune cells, modified in a lab to attack cancer cells, then given back to you intravenously.
This study tests a personalized cell treatment called CAR-T for people whose blood cancer (like lymphoma, leukemia, or chronic lymphocytic leukemia) has come back or not gotten better after standard treatment. The therapy uses your own immune cells, modified in a lab, to find and fight the cancer.
This trial tests whether CAR-T cells, a type of immunotherapy that targets specific markers on cancer cells, can treat blood cancers that have come back or not responded to standard treatment. It may offer a new option for people with lymphoma, leukemia, or multiple myeloma.
Hear when a new Hematologic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.